Gerren McHam, vice president of Government and External Affairs, API Innovation Center, explains how the organization works at the intersection of industry and federal policy to bridge differing views on what realistic reshoring looks like. McHam identifies the central friction point as the economic reality faced by the generic pharmaceutical industry, which often operates with low returns on investment. In this context, manufacturers require strong certainty of demand before committing capital to new or expanded domestic facilities. McHam notes that federal investment in domestic manufacturing, while important, does not automatically guarantee that manufacturers will see reshoring as a sound business decision. To address these challenges, McHam describes the API Innovation Center’s focus on advanced manufacturing technologies and process innovations that lower production costs.